InsiderClue
← All stocks

OKYO Pharma Ltd

OKYO Net buying
CIK 0001849296 #4479 in the set updated 22 Sep 2026
Bought (120 mo)
$762.49K
out of their own pocket, the only kind of buying there is
Sold (120 mo)
$0.00
$0.00 on a plan · $0.00 straight out of an exercise
Sold at will
$0.00
0 of 0 sales
Net
+$762.49K
+$762.49K against sales at will

By person

6 insiders · 5 transactions
Insider
Role
Bought
Sold
Net
Holding
Worth
Change
CERRONE GABRIELE M
Director
$687.49K (3)
—
+$687.49K
10,936,416
$16.40M
+327.7%
JACOB GARY S
CHIEF DEVELOPMENT OFFICER
$50.00K (1)
—
+$50.00K
124,920
$187.38K
+14.7%
BRANCACCIO JOHN P
Director
$25.01K (1)
—
+$25.01K
35,201
$52.80K
+160.2%
Patil Rajkumar V.
Chief Scientific Officer
—
—
—
20,030
$30.05K
+20.2%
Mantelli Flavio
CHIEF MEDICAL OFFICER
—
—
—
20,000
$30.00K
—
Dempsey Robert John
CHIEF EXECUTIVE OFFICER
—
—
—
15,000
$22.50K
—

No percentages here. These insiders hold more than one class of share between them, and the share count on file covers one of them rather than all. Dividing the two would compare different things.

Individual transactions

5
Insider
Date
Role
Action
Shares
Price
Amount
BRANCACCIO JOHN P
15 Sep 2023
Director
Buy
16,670
$1.50
$25.01K
CERRONE GABRIELE M
19 May 2022
Non-Executive Chairman
Buy indirect
37,500
$4.00
$150.00K
JACOB GARY S
19 May 2022
Chief Executive Officer
Buy
12,500
$4.00
$50.00K
CERRONE GABRIELE M
19 May 2022
Executive Chairman
Buy indirect
5,800,000
$0.08
$440.80K
CERRONE GABRIELE M
17 May 2022
Non-Executive Chairman
Buy indirect
1,625,000
$0.06
$96.69K
Show all 5 transactions →

What was left out

Form 4 filings counted 18
Amendments (4/A) skipped 8
Filings about a different issuer 0
Unreadable filings 0
Joint filings 0
Sales on a Rule 10b5-1 plan 0
Sales straight out of an exercise 0
Sales at will 0
Transactions with no price 0
Shares from compensation/vesting 963,902
History held since 18 May 2022